Buscar Búsqueda de estructuras
wx_img
Inquiry Form
  1. Home
  2. DCC-3116

DCC-3116

DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells, by inhibiting the ULK1/2 kinases, which have been shown to be the initiating factors that activate autophagy. DCC-3116 in combination with RAS/MAP kinase signaling pathway inhibition has the potential to change the treatment of RAS/RAF cancers.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

2-Ethyl-4-(4-methylpiperazin-1-yl)aniline
2-Ethyl-4-(4-methylpiperazin-1-yl)aniline
CM1077559
2543681-99-6
1-Methyl-4-(4-nitro-3-vinylphenyl)piperazine
1-Methyl-4-(4-nitro-3-vinylphenyl)piperazine
CM1077560
2543681-91-8
1-(3-Bromo-4-nitrophenyl)-4-methylpiperazine
1-(3-Bromo-4-nitrophenyl)-4-methylpiperazine
CM1077561
166818-85-5
4-chloro-2-(methylthio)-5-(trifluoromethyl)pyrimidine
4-chloro-2-(methylthio)-5-(trifluoromethyl)pyrimidine
CM128233
919116-36-2
tert-butyl (3-(5-oxo-1,4-oxazepan-4-yl)propyl)carbamate
tert-butyl (3-(5-oxo-1,4-oxazepan-4-yl)propyl)carbamate
CM1077562
2542345-19-5